Catheter is placed called Tunneled indwelling pleural catheter, so you can have pleural effusion at home. Draining the catheter 2-3 times week or as directed by the physician. Expert opinion from ...

LTI-01 is currently in a Phase 2, randomized, placebo-controlled, double-blind, dose-ranging study evaluating LTI-01 in patients with infected, non-draining loculated pleural effusions.

Lung Therapeutics is developing two primary drugs: LTI-01 to treat loculated pleural effusion, a serious complication of pneumonia, and LTI-03 to treat idiopathic pulmonary fibrosis.

A 76-year-old woman with a history of gastric adenocarcinoma and chronic kidney disease presented with lethargy and altered mental status. She had anemia and thrombocytopenia; MRI showed foci of re ...

AUSTIN, Texas, March 14, 2017 /PRNewswire/ -- Lung Therapeutics, Inc., a clinical stage pharmaceutical company focused on niche, orphan drug indic ...

Rein also provided an update on its pipeline, highlighting LTI-01, a Phase 2b-ready therapy for loculated pleural effusions, which holds Orphan Drug Designation for pleural empyema.

Lung Therapeutics announced that it received Orphan Drug Designation for LTI-01, an injectable designed for the treatment of loculated pleural effusion. Lung Therapeutics, a pharmaceutical company ...

Clinical-stage biopharmaceutical company Lung Therapeutics announces new Chief Financial Officer Charles T. Garner and new Board Member R.A. Session.

Aileron Therapeutics, Inc. Topline results from Phase 1b study of LTI-03, a novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected to be ...

Texas startup Lung Therapeutics has got off a $14.3 million series B round as it eyes the cash boost for its trials in fibrosis, lung injury and disease.

Mediastinal or hilar lym phadenopathy occurs in up to 10% of cases; pleural effusions, up to 25%. Computed tomography is superior to radiography in the diagnosis of tracheobronchial tuberculosis. CT ...